Login to Your Account



Genelabs' Shares Soar 430% on $57M GSK Buyout Bid

By Donna Young


Friday, October 31, 2008
GlaxoSmithKline plc made a bid to buy Redwood City, Calif.-based Genelabs Technologies Inc. for $1.30 per share, or about $57 million, in cash in a deal aimed at strengthening the London-based drug giant's product platform for hepatitis C virus (HCV) therapies. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription